Research Recommendations Snapshot - Mar 2024
These recommendations offer diverse perspectives on the performance of various companies, ranging from positive to neutral and negative outlooks. Each assessment includes target prices and ratings, providing valuable insights for investors. Whether it's a buy, sell, or hold recommendation, these insights guide investors in making informed decisions about these stocks. Recommendations from Various Fund Houses
CLSA on DMart:
CLSA suggests initiating a Buy on DMart, setting a target price of Rs 5107 per share, expressing positivity towards the company's prospects.
HSBC on Cummins:
HSBC advises upgrading Cummins to a Buy, with a target price of Rs 3300 per share, expressing optimism about the company's performance.
MOSL on Reliance Ind:
Maintaining a Buy recommendation on Reliance Industries, MOSL sets a target price of Rs 3210 per share, indicating a positive outlook on the company.
BNP on Bajaj Finance:
BNP recommends maintaining an Outperform rating on Bajaj Finance, with a target price of Rs 9040 per share, expressing positivity towards the company's performance.
BofA on Bajaj Finance:
BofA suggests maintaining a Buy on Bajaj Finance, setting a target price of Rs 9175 per share, indicating optimism regarding the company's future.
Macquarie on ACC:
Macquarie maintains a Neutral stance on ACC while raising the target price to Rs 2592 per share from Rs 2128 per share, reflecting a positive adjustment in their outlook.
Macquarie on Shree Cement:
Similarly, Macquarie maintains a Neutral stance on Shree Cement, raising the target price to Rs 27034 per share from Rs 25149 per share, indicating a positive sentiment towards the company's performance.
Investec on BSE:
Investec maintains a Buy recommendation on BSE, with a target price of Rs 2800 per share, expressing confidence in the company's potential.
MOSL on Gland Pharma:
MOSL advises maintaining a Buy on Gland Pharma, setting a target price of Rs 2240 per share, indicating positive expectations for the company's growth.
Citi on IOC:
Citi suggests maintaining a Buy on IOC, with a target price of Rs 179 per share, expressing positivity towards the company's prospects.
Jefferies on Bharti Airtel:
Jefferies recommends maintaining a Buy on Bharti Airtel, with a target price of Rs 1300 per share, indicating optimism about the company's performance.
Jefferies on MGL:
Similarly, Jefferies advises maintaining a Buy on MGL, raising the target price to Rs 1540 per share, reflecting positive expectations for the company's growth.
HSBC on Cipla:
HSBC maintains a Buy recommendation on Cipla, setting a target price of Rs 1585 per share, expressing confidence in the company's prospects.
Citi on AU Small Bank:
Citi suggests maintaining a Neutral stance on AU Small Bank, with a reduced target price of Rs 622 per share, reflecting a neutral outlook on the bank's performance.
Citi on NMDC:
Similarly, Citi maintains a Sell recommendation on NMDC, with a reduced target price of Rs 180 per share, indicating a neutral stance on the company.
Citi on Petronet:
Citi also suggests maintaining a Sell on Petronet, with a reduced target price of Rs 220 per share, reflecting a neutral outlook on the company.
Macquarie on Ambuja Cem:
Macquarie downgrades Ambuja Cem to Neutral, while raising the target price to Rs 608 per share from Rs 501 per share, indicating a neutral stance on the company.
Macquarie on Dalmia Bharat:
Maintaining an Outperform rating on Dalmia Bharat, Macquarie reduces the target price to Rs 2233 per share from Rs 2503 per share, reflecting a neutral outlook.
Macquarie on Ramco Cement:
Macquarie maintains a Neutral stance on Ramco Cement, lowering the target price to Rs 876 per share from Rs 1000 per share, indicating a neutral outlook on the company.
MS on Wipro:
MS suggests maintaining an Underweight stance on Wipro, with a target price of Rs 475 per share, reflecting a neutral outlook on the company's performance. Join our WhatsApp Group for Trading/Investment ideas & Market Updates👇
DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matters published here are purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on the information published here. Any reader making decisions based on any information published here does so entirely at their own risk. Investors should bear in mind that any investment in the stock market is subject to unpredictable market-related risks. The author has no plans to invest in this offer and also the author does not recommend investing in any offer published on this website.